Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 5Active not recruiting 2Withdrawn 1Unknown 1Terminated 1Not yet recruiting 1Completed 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Triple Negative Breast Neoplasms 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasm Metastasis 1Leukemia, Myeloid, Acute 1Leukemia, Biphenotypic, Acute 1Burkitt Lymphoma 1Breast Neoplasms 1

Interventions

Cytarabine 25Azacitidine 17fludarabine phosphate 15fludarabine 15Cyclophosphamide 14venetoclax 8Peripheral Blood Stem Cell Transplantation 8Methotrexate 8Busulfan 8Granulocyte Colony-Stimulating Factor 7Filgrastim 7Whole-Body Irradiation 6Decitabine 6Cyclosporine 6Injections 5Idarubicin 5decitabine and cedazuridine drug combination 4Tacrolimus 4Radiotherapy 4Mycophenolic Acid 4Mitoxantrone 4Daunorubicin 4Cladribine 4CPX-351 4Biopsy 4midostaurin 3merphos 3magrolimab 3gilteritinib 3Stem Cell Transplantation 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Leukemia, Myeloid, Acute × Liposomes × Clear all
NCT05320380 2023-09-01

A Study of the Drug IMGN632 in Children With Leukemia That Has Come Back After Treatment or is Difficult to Treat

Children's Oncology Group

Phase 1/2 Withdrawn
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡